B-cell development and differentiation

Air pollution and systemic immune biomarkers in early life: A systematic review

INTRODUCTION

Children's rapid development and immature immune systems place them at a higher risk of adverse health outcomes associated with air pollution exposure. However, the specific mechanisms in which air pollution mediates immune dysregulation in youth are poorly understood. Thus, we aimed to systematically review the available epidemiological evidence surrounding the effects of indoor and ambient air pollution exposure on systemic immune biomarkers in early life (from birth to 18 years old).

METHODS

based on PRISMA guidelines, we developed a systematic search strategy and defined inclusion and exclusion criteria to retrieve publications from PubMed, SCOPUS and Web of Science published up to August 10th, 2024. Quality assessment and evidence evaluation were also performed. Five independent reviewers participated in the process.

RESULTS

In total, 96 studies were included. We found limited evidence of a causal relationship between prenatal ambient PM2.5 and reduced T-cells (CD3+ and CD8+), as well as between postnatal PM exposure and increased IgE levels or allergic sensitization. For the rest of exposure-outcome combinations we classified the evidence as inadequate, mainly due to the limited number of studies available or the lack of consistency in the results obtained among them. This was particularly the case for indoor air pollution research, for which only 12 studies were available.

CONCLUSION

the present systematic review highlights the need for further research on the impacts of air pollution on youth's immune system. We provided recommendations for future studies in order to better understand the early subclinical and clinical effects of air pollution and the underlying biological pathways, and identify the dynamics of the innate and adaptive immune responses to environmental threats. Considering the significance of childhood immunity on health outcomes within all stages of life, and the globally extensive burden of air pollution exposure, further research on this topic should be prioritized.

A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma

Background: Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease that can have profound differences in survival outcomes. A variety of powerful prognostic factors and models have been constructed; however, the development of more accurate prognosis prediction and targeted treatment for DLBCL still faces challenges. An explosion of research on super-enhancer (SE)–associated genes provide the possibility to use in prognostication for cancer patients. Here, we aimed to establish a novel effective prognostic model using SE-associated genes from DLBCL.

Methods: A total of 1,105 DLBCL patients from the Gene Expression Omnibus database were included in this study and were divided into a training set and a validation set. A total of 11 SE-associated genes (BCL2, SPAG16, PXK, BTG1, LRRC37A2, EXT1, TGFBR2, ANKRD12, MYCBP2, PAX5, and MYC) were initially screened and identified by the least absolute shrinkage and selection operator (Lasso) penalized Cox regression, univariate and multivariate Cox regression analysis. Finally, a risk score model based on these 11 genes was constructed.

Results: Kaplan–Meier (K–M) curves showed that the low-risk group appeared to have better clinical survival outcomes. The excellent performance of the model was determined via time-dependent receiver operating characteristic (ROC) curves. A nomogram based on the polygenic risk score was further established to promote reliable prognostic prediction. This study proposed that the SE-associated-gene risk signature can effectively predict the response to chemotherapy in DLBCL patients.

Conclusion: A novel and reliable SE-associated-gene signature that can effectively classify DLBCL patients into high-risk and low-risk groups in terms of overall survival was developed, which may assist clinicians in the treatment of DLBCL.